Stop Treatment, Guarantee Lasting Results
Immunotherapy‘s Lasting Impact on Lung Cancer Patients
Table of Contents
- Immunotherapy’s Lasting Impact on Lung Cancer Patients
- Immunotherapy’s Lasting Impact on Lung Cancer Patients: A Q&A
- What is Immunotherapy for Lung Cancer?
- What is Non-Small Cell Lung Cancer (NSCLC)?
- Does Immunotherapy Always Continue Benefits in NSCLC Patients?
- Can Halting Immunotherapy Affect Results in NSCLC Patients?
- Who Led the Study on Immunotherapy and NSCLC?
- What Journal Published the Study?
- Why Do Some Patients Have to Stop Immunotherapy?
- What are the Concerns When Stopping Immunotherapy?
- Can Patients Experience Continued Benefits After Stopping Immunotherapy?
- What Does “Long-Term Disease Control” Mean?
- What Did the Researchers Conclude About the Study?
- What are Immune Checkpoint Inhibitors (ICIs)?
- What is the Goal of Immunotherapy?
- Side Effects and the Dilemma Doctors Face
For some lung cancer patients, halting immunotherapy treatment does not necessarily negate its positive effects, according to a recent study. Researchers have found that a subset of individuals with non-small cell lung cancer (NSCLC) can experience continued benefits even after immunotherapy is stopped.
The study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research, was led by Mark Awad, MD, head of the thoracic oncology service at Memorial Sloan Kettering Cancer Center. Federica pecci, MD, a researcher at Dana Farber Cancer Institute, is credited as the study’s first author.
Balancing Lung Cancer Control and Immunotherapy side Effects
“When immunotherapy activates the immune system, the goal is to selectively affect cancer cells. But this activation can also cause inflammation to other organs,” Awad said. He noted the dilemma clinicians face when side effects emerge: whether to continue, temporarily pause, or permanently discontinue immunotherapy.
Researchers report that between 3% and 12% of patients receiving a single immune checkpoint inhibitor (ICI) and up to 25% on a dual ICI combination may need to cease treatment due to adverse reactions.A significant concern for these patients is the potential for cancer progression or recurrence following treatment cessation.
The study sought to characterize outcomes for NSCLC patients who discontinued ICI therapy. The findings suggest that a subgroup of patients who stopped immune checkpoint inhibitors due to immune-related adverse events maintained long-term disease control.
Pecci stated, “These results suggest that patients may experience prolonged disease control and survival after interruption of treatment due to toxicity or if the side effects affect their quality of life.”
Immunotherapy’s Lasting Impact on Lung Cancer Patients: A Q&A
What is Immunotherapy for Lung Cancer?
Immunotherapy is a type of cancer treatment that uses the body’s own immune system to fight cancer cells. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy works by boosting the immune system’s ability to recognise and destroy cancer cells.
What is Non-Small Cell Lung Cancer (NSCLC)?
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
Does Immunotherapy Always Continue Benefits in NSCLC Patients?
No, not always. While immunotherapy has shown notable promise in treating NSCLC, some patients may need to stop treatment due to side effects or other reasons.
Can Halting Immunotherapy Affect Results in NSCLC Patients?
According to recent research, stopping immunotherapy doesn’t always negate its positive effects.A study found that some NSCLC patients can continue to experience benefits even after stopping immunotherapy.
Who Led the Study on Immunotherapy and NSCLC?
The study was led by Mark Awad, MD, head of the thoracic oncology service at Memorial Sloan Kettering Cancer Center. Federica Pecci, MD, a researcher at Dana Farber Cancer Institute, is credited as the study’s first author.
What Journal Published the Study?
The study was published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Why Do Some Patients Have to Stop Immunotherapy?
Patients may need to stop immunotherapy due to adverse reactions, which can be severe. According to the provided article:
Adverse Reactions: The immune system activation caused by immunotherapy can sometimes cause inflammation in other organs.
Percentage of Patients:
Between 3% and 12% of patients receiving a single immune checkpoint inhibitor (ICI) may need to stop treatment.
Up to 25% of patients on a dual ICI combination may need to cease treatment due to adverse reactions.
What are the Concerns When Stopping Immunotherapy?
A primary concern when stopping immunotherapy is the potential for cancer progression or recurrence.
Can Patients Experience Continued Benefits After Stopping Immunotherapy?
Yes, the study suggests that a subgroup of NSCLC patients who stopped immune checkpoint inhibitors due to immune-related adverse events maintained long-term disease control.
What Does “Long-Term Disease Control” Mean?
This means the immunotherapy, even after treatment is stopped due to side effects or other reasons, helped the cancer from worsening or returning for an extended period.
What Did the Researchers Conclude About the Study?
The results suggest that some patients may experience prolonged disease control and survival after stopping treatment due to toxicity or if the side effects affect their quality of life, according to Federica Pecci.
What are Immune Checkpoint Inhibitors (ICIs)?
ICIs are a type of immunotherapy that work by blocking specific proteins (immune checkpoints) that prevent the immune system from attacking cancer cells.
What is the Goal of Immunotherapy?
The goal of immunotherapy is to selectively affect cancer cells. Though, it’s also critically important to manage the side effects from this activation.
Side Effects and the Dilemma Doctors Face
When side effects emerge during immunotherapy, doctors face the dilemma of how to proceed with treatment.This includes:
Continuing the treatment
Temporarily pausing treatment
* Permanently discontinuing treatment
Summary of Immunotherapy Outcomes after Treatment Cessation
| Feature | Description |
| :———————– | :—————————————————————————————————————————————————————————- |
| Patient Subset | A subgroup of NSCLC patients who stopped ICIs due to immune-related adverse events.|
| Observed Outcome | Maintained long-term disease control. |
| Led Researcher | Federica Pecci, MD |
| Key Suggestion | Patients may experience prolonged disease control and survival after interruption of treatment in some cases, especially due to toxicity or if side effects affect quality of life. |